DLBS3233 clinical trials
Also written DLBS3233.
How each study uses DLBS3233 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the DLBS3233 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2021 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Dexa Medica Group (6) · Inlacinpenelitian (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses DLBS3233 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- The Effect of Therapy Combination in PCOS With Dlbs 3233RecruitingEarly Phase 1InlacinpenelitianNCT07403201Written as dlbs 3233 , clomifen citrat
- The Efficacy and Safety of DLBS3233 in Adults With PrediabetesCompletedPhase 3Dexa Medica GroupNCT07937449Written as DLBS3233
- PCOS Treatment Using DLBS3233, Metformin, and Combination of BothCompletedPhase 3Dexa Medica GroupNCT01999686Written as DLBS3233
- Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)CompletedPhase 3Dexa Medica GroupNCT01733459Written as DLBS3233
- Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes MellitusCompletedPhase 3Dexa Medica GroupNCT01645332Written as DLBS3233
- Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes MellitusCompletedPhase 3Dexa Medica GroupNCT01472614Written as DLBS3233
- Efficacy and Safety of DLBS3233 in Prediabetic PatientsCompletedPhase 3Dexa Medica GroupNCT01531933Written as DLBS3233
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- The Efficacy and Safety of DLBS3233 in Adults With PrediabetesNov 16, 2026NCT07937449